State Street’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.1M | Sell |
11,614,006
-2,073,555
| -15% | -$2.85M | ﹤0.01% | 2346 |
|
|
2025
Q4 | $22M | Buy |
13,687,561
+1,842,792
| +16% | +$3.86M | ﹤0.01% | 2211 |
|
|
2025
Q3 | $32.3M | Buy |
11,844,769
+3,847,616
| +48% | +$12.8M | ﹤0.01% | 1972 |
|
|
2025
Q2 | $29.1M | Buy |
7,997,153
+1,191,346
| +18% | +$3.27M | ﹤0.01% | 1975 |
|
|
2025
Q1 | $13.1M | Buy |
6,805,807
+501,109
| +8% | +$1.02M | ﹤0.01% | 2360 |
|
|
2024
Q4 | $12M | Buy |
6,304,698
+2,874,171
| +84% | +$4.99M | ﹤0.01% | 2523 |
|
|
2024
Q3 | $4.53M | Buy |
3,430,527
+683,287
| +25% | +$912K | ﹤0.01% | 3010 |
|
|
2024
Q2 | $2.8M | Buy |
2,747,240
+2,096,890
| +322% | +$2.59M | ﹤0.01% | 3179 |
|
|
2024
Q1 | $1.19M | Buy |
650,350
+39,800
| +7% | +$63.6K | ﹤0.01% | 3426 |
|
|
2023
Q4 | $757K | Sell |
610,550
-45,900
| -7% | -$46.8K | ﹤0.01% | 3541 |
|
|
2023
Q3 | $748K | Buy |
656,450
+30,400
| +5% | +$39K | ﹤0.01% | 3594 |
|
|
2023
Q2 | $573K | Sell |
626,050
-66,786
| -10% | -$64.5K | ﹤0.01% | 3659 |
|
|
2023
Q1 | $388K | Buy |
692,836
+120,900
| +21% | +$92.4K | ﹤0.01% | 3832 |
|
|
2022
Q4 | $330K | Hold |
571,936
| – | – | ﹤0.01% | 3913 |
|
|
2022
Q3 | $181K | Sell |
571,936
-1,940
| -0.3% | -$761 | ﹤0.01% | 4194 |
|
|
2022
Q2 | $203K | Sell |
573,876
-10,914,348
| -95% | -$4.58M | ﹤0.01% | 4189 |
|
|
2022
Q1 | $8.25M | Sell |
11,488,224
-255,237
| -2% | -$546K | ﹤0.01% | 2925 |
|
|
2021
Q4 | $26.5M | Sell |
11,743,461
-4,112,967
| -26% | -$11.2M | ﹤0.01% | 2256 |
|
|
2021
Q3 | $45.7M | Buy |
15,856,428
+1,849,791
| +13% | +$5.28M | ﹤0.01% | 1874 |
|
|
2021
Q2 | $53.1M | Sell |
14,006,637
-3,037,539
| -18% | -$10.2M | ﹤0.01% | 1797 |
|
|
2021
Q1 | $57.7M | Sell |
17,044,176
-5,432,358
| -24% | -$19.6M | ﹤0.01% | 1634 |
|
|
2020
Q4 | $62.9M | Buy |
22,476,534
+7,136,063
| +47% | +$20.8M | ﹤0.01% | 1494 |
|
|
2020
Q3 | $38.5M | Buy |
15,340,471
+10,328,433
| +206% | +$90.6M | ﹤0.01% | 1637 |
|
|
2020
Q2 | $68.1M | Buy |
5,012,038
+1,595,108
| +47% | +$16.5M | ﹤0.01% | 1235 |
|
|
2020
Q1 | $25.9M | Sell |
3,416,930
-25,066
| -0.7% | -$195K | ﹤0.01% | 1680 |
|
|
2019
Q4 | $21.8M | Sell |
3,441,996
-203,661
| -6% | -$968K | ﹤0.01% | 2082 |
|
|
2019
Q3 | $14.3M | Sell |
3,645,657
-2,153,025
| -37% | -$9.23M | ﹤0.01% | 2284 |
|
|
2019
Q2 | $28.1M | Buy |
5,798,682
+2,416,715
| +71% | +$13.7M | ﹤0.01% | 1880 |
|
|
2019
Q1 | $27.7M | Buy |
3,381,967
+744,121
| +28% | +$5.11M | ﹤0.01% | 1835 |
|
|
2018
Q4 | $14.6M | Buy |
2,637,846
+356,704
| +16% | +$2.79M | ﹤0.01% | 2205 |
|
|
2018
Q3 | $20.1M | Buy |
2,281,142
+350,738
| +18% | +$3.14M | ﹤0.01% | 2178 |
|
|
2018
Q2 | $19.3M | Buy |
1,930,404
+430,191
| +29% | +$4.31M | ﹤0.01% | 2154 |
|
|
2018
Q1 | $14.3M | Buy |
1,500,213
+13,974
| +0.9% | +$195K | ﹤0.01% | 2274 |
|
|
2017
Q4 | $22.1M | Buy |
1,486,239
+197,353
| +15% | +$3.27M | ﹤0.01% | 1981 |
|
|
2017
Q3 | $25.4M | Buy |
1,288,886
+341,998
| +36% | +$5.26M | ﹤0.01% | 1858 |
|
|
2017
Q2 | $13.6M | Buy |
946,888
+399,160
| +73% | +$5.06M | ﹤0.01% | 2240 |
|
|
2017
Q1 | $5.04M | Buy |
547,728
+16,147
| +3% | +$158K | ﹤0.01% | 2689 |
|
|
2016
Q4 | $5.53M | Buy |
531,581
+17,817
| +3% | +$153K | ﹤0.01% | 2641 |
|
|
2016
Q3 | $4.65M | Buy |
513,764
+27,431
| +6% | +$233K | ﹤0.01% | 2600 |
|
|
2016
Q2 | $3.63M | Buy |
486,333
+63,562
| +15% | +$555K | ﹤0.01% | 2790 |
|
|
2016
Q1 | $3.81M | Buy |
422,771
+118,561
| +39% | +$961K | ﹤0.01% | 2690 |
|
|
2015
Q4 | $3.93M | Buy |
304,210
+27,072
| +10% | +$276K | ﹤0.01% | 2670 |
|
|
2015
Q3 | $2.68M | Buy |
277,138
+46,028
| +20% | +$422K | ﹤0.01% | 2862 |
|
|
2015
Q2 | $2.38M | Buy |
231,110
+127,816
| +124% | +$1.09M | ﹤0.01% | 2994 |
|
|
2015
Q1 | $1.15M | Buy |
103,294
+4,678
| +5% | +$49.8K | ﹤0.01% | 3203 |
|
|
2014
Q4 | $1.14M | Buy |
98,616
+23,407
| +31% | +$336K | ﹤0.01% | 3228 |
|
|
2014
Q3 | $1.67M | Buy |
75,209
+2,227
| +3% | +$51.2K | ﹤0.01% | 3090 |
|
|
2014
Q2 | $2.03M | Buy |
+72,982
| New | +$1.76M | ﹤0.01% | 3064 |
|
Other funds holding AKBA
VCM
VPM
State Street's AKBA Position: Q1 2026 in Review
State Street reduced its Akebia Therapeutics (AKBA) stake by 15% in Q1 2026, selling an estimated $2.85M and leaving 11,614,006 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2346.
State Street first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $68.1M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- State Street held 11,614,006 shares of Akebia Therapeutics worth $16.1M as of Q1 2026.
- State Street sold 2,073,555 Akebia Therapeutics shares in Q1 2026, an estimated $2.85M.
- Akebia Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2346 holding.
- State Street first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
- State Street's Akebia Therapeutics position peaked at $68.1M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.